To evaluate freedom from amputation in patients identified utilizing clopidogrel following their lower extremity endovascular revascularization (LER).
Methods:
Patients, 65 years of age and older, undergoing LER were identified from Medicare Provider Analysis and Review and Carrier files utilizing International Classification of Diseases diagnosis and Current Procedural Terminology codes. Postprocedural use of clopidogrel was identified using the National Drug Code directory. Outcomes were evaluated.
Results:
A total of 14 353 patients were identified: 5697 (39.7%) with claudication, 1467 (10.2%) with rest pain, and 7189 (50.1%) with ulceration/tissue loss. In all, 5416 (37.7%) patients were identified using clopidogrel after LER. Overall, patients initiated on clopidogrel had lower amputation rates at 30 days (10.34% vs 14.09%; P < .0001), 90 days (14.05% vs 18.71%; P < .0001), and 1 year (19.68% vs 24.06%; P < .0001).
Conclusion:
Utilization of clopidogrel after LER was associated with lower rates of amputation, yet only 38% of the Medicare population was identified as using clopidogrel. Patients with ulceration and tissue loss benefited the most with significantly greater freedom from amputation and overall survival.
RosamondWFlegalKFurieK. Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117
(4):e25–e146.
2.
HirschATHaskalZJHertzerNR. ACC/AHA 2005 Practice Guidelines for the management of patients with PAD (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113
(11):e463–e654.
3.
American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care. 2003;26
(12):3333–3341.
4.
GoodneyPPBeckAWNagleJWelchHGZwolakRM. National trends in lower extremity bypass surgery, endovascular interventions, and major amputations. J Vasc Surg. 2009;50
(1):54–60.
5.
HenkeP. What is the optimum perioperative drug therapy following lower-extremity vein bypass surgery. Semin Vasc Surg. 2009;22
(4):245–251.
6.
HirschATHaskalZJHertzerNR. ACC/AHA Guidelines for the Management of Patients with Peripheral Arterial Disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease)—summary of recommendations. J Vasc Intervent Radiol. 2006;17(9):1383–1397; quiz 1398.
7.
Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324
(7329):71–86.
8.
AdamDJBeardJDClevelandT. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005;366
(9501):1925–1934.
9.
AllemangMTRajaniRRNelsonPRHingoraniAKashyapVS. Prescribing patterns of antiplatelet agents are highly variable after lower extremity endovascular procedures. Ann Vasc Surg. 2013;27
(1):62–67.
10.
BeardonPHMcGilchristMMMcKendrickADMcDevittDGMacDonaldTM. Primary non-compliance with prescribed medication in primary care. BMJ. 1993;307
(6908):846–848.
11.
WallingAD. Clopidogrel plus aspirin reduces mortality from MI. Am Fam Physician. 2006;74
(1):170.
12.
ValentineRJGrayburnPAEichhornEJMyersSIClagettGP. Coronary artery disease is highly prevalent among patients with premature peripheral vascular disease. J Vasc Surg. 1994;19
(4):668–674.
TodoranTMConnorsGEngelsonBASobieszczykPSEisenhauerACKinlayS. Femoral artery percutaneous revascularization for patients with critical limb ischemia: outcomes compared to patients with claudication over 2.5 years. Vasc Med. 2012;17
(3):138–144.
16.
BecqueminJP.Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. Etude de la Ticlopidine apres Pontage Femoro-Poplite and the Association Universitaire de Recherche en Chirurgie. N Engl J Med. 1997;337
(24):1726–1731.
17.
SchomigANeumannFJKastratiA. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996;334
(17):1084–1089.
18.
LeonMBBaimDSPopmaJJ. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339
(23):1665–1671.
19.
LoRCDarlingJBensleyRP. Outcomes following infrapopliteal angioplasty for critical limb ischemia. J Vasc Surg. 2013;57(6):1455–1463; discussion 1463-1454.
20.
Collaborative overview of randomised trials of antiplatelet therapy—II: maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration. BMJ. 1994;308(6922):159–168.
21.
GirolamiBBernardiEPrinsMH. Antiplatelet therapy and other interventions after revascularisation procedures in patients with peripheral arterial disease: a meta-analysis. Eur J Vasc Endovasc Surg. 2000;19
(4):370–380.
22.
MoulikPKMtongaRGillGV. Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology. Diabetes Care. 2003;26
(2):491–494.
23.
JaarBGAstorBCBernsJSPoweNR. Predictors of amputation and survival following lower extremity revascularization in hemodialysis patients. Kidney Int. 2004;65
(2):613–620.
24.
GrdinicAVojvodicDDjukanovicN. PCI and clopidogrel: antiplatelet responsiveness and patient characteristics. Acta Cardiol. 2011;66
(3):333–340.
